- Joint Effort Needed to Unwind Stimulus: APEC Leaders
- Obama to Outline Strategy to Boost US Exports to Asia
- Friday May See 'Risk Trade' Stalling; Dollar in Focus
- Former Bankers Look to Buy Failing Banks: Report
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Cities With the Most Home Price Reductions
- JAP Posts $1.5 Billion Loss, No Guidance
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- EXCERPTS and IMAGES: Warren Buffett & Bill Gates - Keeping America Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- US commerce secretary: Trade pacts must wait
- French economy expands 0.3 pct in Q3
- Iberia reports euro16.4 million Q3 loss
- Chesapeake crabbers not going for Va.'s buyout
- UK's Balfour Beatty acquires SpawMaxwell of Texas
- China rejects $28B in steel, chemical projects
- Boeing says first 747-8 emerges from factory
- Family hurt in Texas pipeline explosion files suit
- Vegas nightclub owners file for bankruptcy in Fla.
Text Size 
NEW YORK - Impax Laboratories Inc. confirmed Friday it is challenging the patents on Abbott Laboratories' cholesterol drug TriCor, and that Abbott is suing Impax for patent infringement.
Impax, of Hayward, Calif., said it requested marketing approval for generic versions of 48 milligram and 145 milligram TriCor tablets. Abbott filed suit on Thursday in the U.S. District Court for the District of New Jersey. The lawsuit means the Food and Drug Administration cannot approve Impax's drug for 30 months, or until the litigation is resolved.
Annual sales of TriCor, or fenofibrate, are more than $1 billion. The patents protecting TriCor will start to expire in January 2011, opening the door to competition from low cost generics.
Impax's stock slipped 2 cents to close Friday at $8.88. Shares of Chicago-based Abbott lost 29 cents to $50.57.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- They may have wrecked their companies or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes